We intend to pursue targets in North America, Europe and Asia (excluding China) in the media and entertainment industry. We shall not undertake our initial business combination with any entity with its principal business operations in China (including Hong Kong and Macau). (New blank-check company or SPAC incorporated in Delaware) We intend to focus specifically […]

We are a preclinical biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Our vision is to change the treatment paradigm for heart disease, the leading cause of death in the world, and in doing so improve and extend the lives of […]

(Note: This is NOT a traditional IPO. IPOScoop has NO CALL on this offering because it is a NASDAQ uplisting from the AIM, which is operated by the London Stock Exchange. The last reported sale price of our common stock on July 23, 2021, was 10 British pounds sterling per share, or about US$13.79 per […]

We are a preclinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. We focus our discovery efforts on small molecule inhibitors of kinases, a class of cellular targets that can play a central role in cancer growth and proliferation.  By prioritizing target selectivity, we believe our drug candidates have the potential to […]

Note: Immuneering Corp. is a preclinical biopharma company. From the prospectus: “We are a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying our deep knowledge of translational bioinformatics to every stage of the drug development process. We have more than a […]

We intend to focus our initial business combination search in the ecommerce sector, specifically on companies offering Software-as-a-Service (“SaaS”) products and services to enterprise customers globally. We currently intend to focus on opportunities that capitalize on the expertise and ability of our management team, particularly our Chairman, M. Blair Garrou; our President and Chief Executive […]

We are a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. Our proprietary RxSight Light Adjustable Lens system (“RxSight system”), comprised of our RxSight Light Adjustable Lens (“LAL”), RxSight Light Delivery Device (“LDD”) and accessories, is the first and only commercially available intraocular lens (“IOL”) technology that enables doctors […]

We are a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics, which we believe have the potential to transform medicine and improve patient outcomes. We have developed the RaniPill capsule, which is our novel, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with […]

At Omega Therapeutics, our goal is to pioneer a new class of DNA-sequence-targeting, mRNA-encoded therapeutics to fundamentally transform human medicine in the service of patients. Our pioneering OMEGA Epigenomic Programming platform is designed to coopt nature’s universal operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. We have deciphered the […]

Our efforts to identify a prospective target business will not be limited to a particular industry or geographic location, although we currently intend to focus on opportunities in Asia. (Incorporated in the British Virgin Islands)  (Note: 8i Acquisition 2 Corp. priced its SPAC IPO on Monday morning, Nov. 22, 2021, in line with the terms […]